Barely Significant
← all excerpts

Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis.

Breast Cancer Res · 2025 · PMC12341277 · PMID 40790607

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantP < 0.001actually significant
As we observed in the full HER2-negative cohort, the benefit of T-DXd over SG was restricted to HR+ tumors and was highly significant for all HER2-negative subsets including HER2-null tumors ( P < 0.001; Table 2 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.